XGN Exagen

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT).

Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at .

A replay of the conference call will be available until Monday, April 1, 2024, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13743861. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

About Exagen Inc.

Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.

For more information, please visit or follow on X (formerly known as Twitter).

Contact:

Ryan Douglas

Exagen Inc.



760.560.1525



EN
07/03/2024

Underlying

XGNExagen

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exagen

 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance...

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the first quarter of 2024, a 28.4% increase over the first quarter of 2023.Delivered gross margin of 59.6% in the first quarter of 2024, compared to a gross margin of 47.2% in the first quarter of 2023. AVISE® CTD trailing twelve-month...

May 13, 2024 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Announces Campaign for Lupus Awareness Month

Exagen Announces Campaign for Lupus Awareness Month CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patients and partnership activities that enhance the impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE). Lupus Awareness Month occurs every May and is an important platform for lupus-focused organizations to educate and advocate for those affected by this complex con...

May 6, 2024 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen to Announce First Quarter 2024 Results on May 13, 2024

Exagen to Announce First Quarter 2024 Results on May 13, 2024 CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT). Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 ...

April 30, 2024 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Announces Changes to the Board of Directors

Exagen Inc. Announces Changes to the Board of Directors CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the University of Illinois. He spent ove...

April 26, 2024 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: Record total revenue of $52.5 million for the full-year 2023, and total revenue of $13.8 million for the fourth quarter of 2023.Record 137,650 AVISE® CTD tests performed for the full-year 2023, including 30,438 tests for the fourth quarter of 2023. Over 900,000 AVISE® CTD te...

March 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch